contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


intellegos-partner-hai-solutions-has-received-fda-approval-for-qikcap

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Intellego Technologies is a company active in photochromic indicator technology. The company supplies photochromic inks that design visual indicators that enable the effects of invisible ultraviolet light to be seen. The ink changes color based on exposure to ultraviolet radiation or specific substances. The products are primarily used by OEM manufacturers and are used in industry applications globally. Intellego Technologies was founded in 2011 and is headquartered in Stockholm.

Intellego Technologies

Intellego Technologies AB (publ) (“Intellego” or the “Company”) announces that the product QIKcap, owned by its partner company HAI Solutions (HAIS), has today received approval from the U.S...

<div class="mfn-preamble"><p><strong>Intellego Technologies AB (publ) (“Intellego” or the “Company”) announces that the product QIKcap, owned by its partner company HAI Solutions (HAIS), has today received approval from the U.S. Food and Drug Administration (FDA). The approval means that QIKcap may now be marketed and used within the U.S. healthcare system.</strong></p></div><div class="mfn-body"><p>QIKcap is based on HAI Solutions’ patented technology, in which Intellego’s photochromic indicator technology constitutes an integrated and essential part of the now approved product.</p><p>Intellego holds an ownership interest of approximately 10.5 percent in HAIS and, in addition, has exclusive rights to sell QIKcap in the Chinese market. Intellego is also entitled to license revenues from global sales of the product.</p><p>“The FDA approval of QIKcap is an important milestone for HAI Solutions and enables future sales opportunities for Intellego in the Chinese market, as well as potential license revenues linked to global sales of QIKcap,” says Jacob Laurin, acting CEO of Intellego Technologies.</p><p>QIKcap is a single-use cap for intravenous access points, primarily catheters. The product combines a photochromic dosimeter and an optical lens to verify UVC exposure, with the aim of reducing the risk of intravenous contamination and bloodstream infections.</p><p>Link to HAI Solutions news: <strong><a rel="noopener" href="https://www.prnewswire.com/news-releases/hai-solutions-receives-fda-de-novo-grant-for-qikcap-system-pioneering-uvc-technology-for-microbial-reduction-on-needleless-iv-connectors-302650330.html">News — HAI Solutions</a></strong></p><p><a rel="noopener" href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?id=DEN250004">Link to FDA approval.</a></p></div><div class="mfn-footer mfn-contacts mfn-79847ae48c06"><p><strong class="mfn-heading-1">Contact</strong></p><hr><p><br></p><p>Jacob Laurin,&nbsp;acting CEO and Board Member, Intellego Technologies AB<br>E-post: <a rel="noopener" href="mailto:jacob.laurin@intellego-technologies.com">jacob.laurin@intellego-technologies.com</a></p></div><div class="mfn-footer mfn-about mfn-d6eb73c4bfb8"><p><strong class="mfn-heading-1">About Us</strong></p><hr><p>Intellego Technologies develops and manufactures color indicators that show the effect of irradiation with, among other things, invisible ultraviolet light, UV light. Color indicators are used globally in, for example, the disinfection industry, the sunscreen industry, and the manufacturing industry. Intellego's indicators have been developed from the company's patented photochromic ink, which can be adapted to different wavelengths of light and various application areas across a range of different industries. Intellego Technologies was founded in 2011, is headquartered in Stockholm, and is listed on the Nasdaq First North Growth Market.</p><p>The company's Certified Adviser on the Nasdaq First North Growth Market Stockholm is Mangold Fondkommission AB.</p><p>Intellego's website: <a rel="noopener" href="https://intellego-technologies.com/en/">https://intellego-technologies.com/en/</a></p><p>Subscribe to Intellego's press releases: <a rel="noopener" href="https://intellego-technologies.com/sv/pressmeddelanden/">https://intellego-technologies.com/sv/pressmeddelanden/</a></p><p>Contact the communications team: <a rel="noopener" href="mailto:communications@intellego-technologies.com">communications@intellego-technologies.com</a></p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-mar"><p><em>This information is information that Intellego Technologies is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-12-30 16:19 CET.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/3a731f73-1822-4b87-aa68-8b533e39b76d/intellegos-partner-hai-solutions-has-received-fda-approval-for-qikcap.pdf" class="mfn-generated mfn-primary">Intellego’s partner HAI Solutions has received FDA approval for QIKcap</a></p></div>